MONTREAL--(BUSINESS WIRE)--Jan. 24, 2006--Caprion Pharmaceuticals Inc. today announced a research collaboration with Berlex Inc., a US affiliate of Schering AG Germany (NYSE: SHR, FSE: SCH). The collaboration will use Caprion's CellCarta(R) proteomics platform to support biomarker discovery. Caprion will identify pharmacodynamic biomarkers in plasma resulting from the administration of Berlex compounds in pre-clinical development. "Caprion is looking forward to working with Berlex on their pre-clinical therapeutic candidates," noted Dr. Daniel Chelsky, Chief Scientific Officer at Caprion. "We believe Caprion's capabilities in the discovery of protein biomarkers will significantly impact our partner's development efforts."
